Category:Cancer treatments
From WikiMD.com Medical Encyclopedia
 | Pages in this category should be moved to subcategories where applicable. This category may require frequent maintenance to avoid becoming too large. It should directly contain very few, if any, pages and should mainly contain subcategories. |
Subcategories
This category has the following 8 subcategories, out of 8 total.
A
C
E
I
R
S
T
V
Pages in category "Cancer treatments"
The following 200 pages are in this category, out of 514 total.
(previous page) (next page)A
- Abituzumab
- ABT-510
- Active immunotherapy
- Active surveillance
- Active surveillance of prostate cancer
- Adc
- ADE (chemotherapy)
- Adecatumumab
- Adegramotide
- Adjuvant therapy
- Adjuvant chemotherapy
- Adoptive cell therapy
- Adoptive cell transfer
- Adoptive immunotherapy
- Advaxis
- ADXS11-001
- AFP-07
- AFPep
- Aldesleukin
- ALECSAT
- ALK inhibitor
- Alpelisib
- Alpha-interferon
- ALT-803
- Alternative cancer treatments
- Altumomab pentetate
- Amatuximab
- AMG 319
- Amphinex
- Angiostatin
- Annamycin
- Anti-idiotypic vaccine
- Anti-VEGF
- Antiangiogenesis
- Antiangiogenic
- Antibody-drug conjugate
- Antibody-drug conjugates
- Antibody–drug conjugate
- Antihormone therapy
- Template:Antineoplastic-agents-stub
- Antineoplastics
- Artificial fever
- Asparaginase erwinia chrysanthemi
- ATC code L01
- Atrasentan
- Auger therapy
- Autologous immune enhancement therapy
- Autologous tumor cell
- Avapritinib
- Avicine
- Axicabtagene ciloleucel
B
C
- C-1027
- C-Met inhibitors
- Camidanlumab tesirine
- Cancer Chemotherapy and Pharmacology
- Cancer drugs
- Cancer therapy
- Cancer Treatment
- Cantuzumab
- Cantuzumab mertansine
- Cantuzumab ravtansine
- Capmatinib
- Capsaicin
- CAR T cell
- CAR T-cell therapy
- CAR-302,196
- Carmustine
- Catumaxomab
- Cellular adoptive immunotherapy
- Che
- Chemo
- Chemoimmunotherapy
- Chemoradiation
- Chemosensitizer
- Chemotherapeutic
- Chemotherapy
- Chemotherapy drug
- Chimeric antigen receptor
- Chimeric antigen receptor T cell
- Cirmtuzumab
- Cisplatin
- Citatuzumab bogatox
- Cixutumumab
- Clevegen
- Clostridium novyi-NT
- Cofetuzumab pelidotin
- Coley's toxins
- Combination chemotherapy
- Conatumumab
- Conization
- Continuous hyperthermic peritoneal perfusion
- Cryoimmunotherapy
- Cryosurgery
- Custirsen
- Cyberknife (device)
- Cytarabine
- Cytoreduction
- Cytostatic
D
- Dabrafenib
- Dacarbazine
- Dacetuzumab
- Dactolisib
- Dalantercept
- Dalotuzumab
- DAT (chemotherapy)
- Debulking
- Defactinib
- Demcizumab
- Depatuxizumab mafodotin
- Detumomab
- Devimistat
- Dinutuximab beta
- Discovery and development of tubulin inhibitors
- Donor lymphocyte infusion
- Dose-dense chemotherapy
- Duligotumab
- Dusigitumab
E
- Ecromeximab
- Edodekin alfa
- Edrecolomab
- Electrochemotherapy
- Emactuzumab
- Enavatuzumab
- Encorafenib
- Endocrine therapy
- Endoscopic mucosal resection
- Endostatin
- Engineered CAR T cell delivery
- Enoblituzumab
- Ensituximab
- Epigenetic therapy
- Erlizumab
- Ertumaxomab
- Estrogen deprivation therapy
- Etoposide
- Etoposide phosphate
- Exagamglogene autotemcel
- Exherin
- Extracorporeal photopheresis
